JT
PHAT icon

Jupiter Topco’s Phathom Pharmaceuticals PHAT Stock Holding History

Jupiter Topco’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$233K Buy
+21,500
New +$245K ﹤0.01% 2371

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco's PHAT Position: Q2 2026 in Review

Jupiter Topco opened a new position in Phathom Pharmaceuticals (PHAT) in Q2 2026: 21,500 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #2371 among its holdings.

146 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Jupiter Topco held 21,500 shares of Phathom Pharmaceuticals worth $233K as of Q2 2026.
  • Phathom Pharmaceuticals was a new Jupiter Topco position in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2371 holding.
  • 146 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.